Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 228 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Foot Pathology Clear all

Conditions: Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Interventions: Engensis (VM202), placebo; Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 25
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Gatos, California + 22 more

Conditions: Diabetic Foot Ulcers (DFUs), Venous Leg Ulcers (VLUs), Pressure Ulcers, Surgical Wound Dehiscence (SWD), Chronic Wounds, Undermined and Tunneling Wounds
Interventions: Acellular Porcine-Derived Wound Matrix; Device
Lead sponsor: Reprise Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Coconut Creek, Florida • Tamarac, Florida

Conditions: Peripheral Artery Disease
Interventions: AFO to improve outcomes; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 40 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Missoula, Montana

Conditions: Diabetic Foot Ulcer, Venous Leg Ulcer
Interventions: Amnion-Intermediate-Chorion, Amnion-Chorion-Amnion, Standard of Care; Other · Procedure
Lead sponsor: Cellution Biologics; Industry
Eligibility: 18 Years to 98 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Jacksonville, Florida • Cincinnati, Ohio • Weslaco, Texas + 1 more

Conditions: Tinea Pedis
Interventions: 33525, Placebo; Drug
Lead sponsor: Medicis Global Service Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Los Angeles, California • Paramus, New Jersey • Albuquerque, New Mexico + 6 more

Conditions: Pain
Interventions: Pain Coping Information, Mindfulness Practice (alone), Mindfulness Introduction + Mindfulness Practice, Pain Introduction + Mindfulness Introduction + Mindfulness Practice; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Bacterial Infections, Diabetic Foot, Osteomyelitis
Interventions: Tigecycline, Ertapenem; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,061 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 26
States / cities: Los Angeles, California • Northridge, California • San Francisco, California + 20 more

Conditions: Breast Cancer, Colorectal Cancer, Pain
Interventions: Capecitabine, Celecoxib, Radiation Therapy, Placebo; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 13
States / cities: Santa Rosa, California • Grand Rapids, Michigan • Kalamazoo, Michigan + 10 more

Conditions: Diabetic Neuropathy, Painful
Interventions: Duloxetine hydrochloride, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Pembroke Pines, Florida

Conditions: Acute Pain
Interventions: Wafermine, Oxycodone, Placebo; Drug
Lead sponsor: iX Biopharma Ltd.; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Nerve Block, General Anesthesia, Spinal Anesthesia, Pain, Postoperative Nausea and Vomiting
Interventions: 25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block, 10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block, Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed, 45-60 mg of 1.5% mepivacaine for spinal anesthesia, LMA insertion + titrated propofol infusion + sevoflurane + ketamine 10 mg/hr for general anesthesia; Procedure · Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Tinea Pedis
Interventions: Naftifine hydrochloride 2%, Placebo, Naftin® 2% (Naftifine hydrochloride 2%); Drug
Lead sponsor: Genzum Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 693 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 12
States / cities: Brandon, Florida • Miami, Florida • Miramar, Florida + 6 more

Conditions: Tinea Cruris, Tinea Pedis
Interventions: UHE-103 Cream, Naftin (naftifine hydrochloride) Cream; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: San Diego, California • Thousand Oaks, California • Austin, Texas + 2 more

Conditions: Wound Healing
Interventions: GSK1278863, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 7
States / cities: Castro Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more

Conditions: Infection, Soft Tissue, Infection, Wound, Cellulitis, Diabetic Foot Ulcer
Interventions: Cefazolin, Silberg Tissue Preparation System; Drug · Device
Lead sponsor: Sonescence, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Sebastopol, California

Conditions: Diabetic Polyneuropathy, Diabetic Foot Ulcer, Diabetes, Foot Infection
Interventions: TempTouch®; Device
Lead sponsor: Diabetica Solutions Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 3
States / cities: New Braunfels, Texas • San Antonio, Texas

Conditions: Critical Limb Ischemia
Interventions: Not listed
Lead sponsor: HyperMed; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain
Interventions: Remodulin® (treprostinil sodium) Injection; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 7
States / cities: Tampa, Florida • Worcester, Massachusetts • Minneapolis, Minnesota + 4 more

Conditions: Postoperative Pain
Interventions: HTX-011, Luer Lock applicator, Vial access device, aprepitant; Drug · Device
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Tinea Pedis, Athlete's Foot
Interventions: Econazole Nitrate Foam 1%, Vehicle Foam; Drug · Other
Lead sponsor: AmDerma; Industry
Eligibility: 12 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Miramar, Florida • Clinton Township, Michigan • Las Vegas, Nevada + 4 more

Conditions: Palmoplantar Psoriasis, Plaque Psoriasis
Interventions: Duobrii®; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Bunions, Postoperative Pain
Interventions: HTX-034 low dose, HTX-034 high dose, Luer lock applicator, Bupivacaine HCl; Drug · Device
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Phoenix, Arizona • Bellaire, Texas • San Antonio, Texas + 1 more

Conditions: Fat Pad Atrophy, Pain
Interventions: Ultrasound of the foot, Pedobarograph Measurements, Manchester Foot Pain and Disability Index; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetic Ulcer
Interventions: Topical wound oxygen therapy, Topical wound oxygen Placebo; Device
Lead sponsor: AOTI Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

Phase 3 Gene Therapy for Painful Diabetic Neuropathy

Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care

Ankle-foot Orthoses for Peripheral Artery Disease

Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcers

Topical Antifungal Treatment for Tinea Pedis

Brief Mindfulness for Foot and Ankle Pain

Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer

A Study for the Treatment of Painful Diabetic Neuropathy

A Study Of The Effectiveness Of Wafermine Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy

Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery.

BE Study of Naftifine HCL

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863

Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion

TempTouch IR Thermometry & Diabetic Patient Self-Care

Validation of OxyVu for Assessing Level of Amputation With Comparison to Other Modalities

Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

Phase 2 Bunionectomy HTX-011 Administration Study

Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

Dose-Escalation Study of HTX-034 Following Bunionectomy

Diagnostic Modeling for Pedal Fat Pad Atrophy

Evaluation of Topical Wound Oxygen (two2) Therapy